Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Indoco Remedies Ltd

| Q4 FY26 Earnings Call

NEUTRAL SENTIMENT

Report Source

⬤11th May 26

Summary : Indoco Remedies reports Q4 FY26 recovery driven by international growth, but faces challenges with high debt, rising receivables, and domestic seasonality.

Management Perspective positive : It gives me great joy to announce that after almost six quarters, we are in positive in this quarter for performance. This performance has been possible due to a great acceleration shown by international formulations business. The OTC business has also done well. The confidence level is pretty high for next 2-3 years on this business.

Concall Report Analysis & Insights

Business Overview

  1. Company achieved positive performance after six quarters, driven by international formulations.
  2. Domestic Q4 performance was muted due to seasonal factors affecting anti-infectives and respiratory segments.
  3. Received US ANDA approvals for liquid orals (Brivaracetam, Lacosamide) and launched Cyclopam extension in India.
  4. Rexidin-M Forte gel is now the most prescribed stomatological brand; company overtook Pfizer in prescription audit.
  5. Hived off ophthal business to Sunway to focus on core ethical business; OTC business is expanding.
  6. Q4 FY26 consolidated net revenues grew 18.8% YoY to INR 4,559 million, with international formulations up 94.6%.

Future Growth Prospects

  1. International formulations business, including regulated and emerging markets, is expected to drive growth.
  2. New liquid oral launches in less crowded US and European markets are planned.
  3. OTC business aims to expand presence through grocers, modern trade, and quick commerce.
  4. Emerging markets (Eastern Africa, French West Africa) show high confidence for 2-3 years of continued growth.
  5. Europe's base contract manufacturing is expected to grow with better margins from efficient plants.

Management Insights

  1. Management expressed joy over positive performance after six quarters, driven by international growth.
  2. Confirmed efforts to reduce borrowings and maintain tight control on CAPEX and operating expenses.
  3. Acknowledged increased receivables due to longer credit periods in international markets.
  4. Stated commitment to supporting the Warren Remedies OTC business for at least three years.
  5. Highlighted strong performance of new product launches in India, contributing significantly to revenue.

Signs of Skepticism

  1. Analysts questioned the significant increase in trade receivables and overall debt levels.
  2. Concerns were raised about rising supplier payables and MSME dues, indicating cash flow issues.
  3. Skepticism regarding domestic business performance, where prescription growth doesn't translate to sales.
  4. Unresolved FDA approval for sterile products and its impact on future approvals.
  5. Questions about the profitability of FPP and Warren Remedies despite sales.

Risk Factors

  1. Macroeconomic factors are not conducive, impacting cost of goods and potential export disruptions.
  2. Elongation of collection periods for international business, especially in emerging markets, affects receivables.
  3. Overall debt levels are a concern, described as "alarming" by analysts.
  4. API plant products are under validation, not yet approved, causing financial strain on Warren Remedies.
  5. Domestic business is susceptible to seasonal shifts, causing performance peaks and troughs.

Good To Know

  1. Q4 FY26 Standalone EBITDA was INR 630 million (14.7% of net sales).
  2. Q4 FY26 Consolidated EBITDA was INR 497 million (10.9% of net sales).
  3. Total consolidated debt is approximately INR 960 crore.
  4. INR 140 crore of short-term debt is scheduled for repayment next year.
  5. No major CAPEX is planned for the next two years.

Key Drivers

  1. International formulations drive strong growth.
  2. New liquid oral ANDAs approved in US.
  3. Emerging markets show high growth potential.
  4. Successful new product launches in India.

Key Analyst Discussions

Competitive Environment

  1. Questions about market share capture for US products like rivaroxaban.
  2. Inquiries about the company's ranking in prescription audits.

Market Trends & Consumer Behavior

  1. Questions on the impact of seasonality on domestic business performance.
  2. Inquiries about the disconnect between prescription growth and actual sales.
  3. Discussion on product availability at the chemist level.

Financial Highlights

  1. Questions on receivables aging, overall debt levels, and MSME payables.
  2. Inquiries about the increase in interest costs due to forex impact.
  3. Clarification sought on FPP's negative net worth and profitability.
  4. Questions regarding the exceptional gain in Q4 and debt repayment schedule.
  5. Inquiry about the current quarter's OTC revenue.

Product Composition

  1. Questions about portfolio optimization and the hiving off of the ophthal division.
  2. Inquiries about the performance of specific products like Cital and stomatologicals.
  3. Questions on the new product sales revenue mix in India.

Strategic Considerations

  1. Questions on growth triggers for regulated markets (Europe, US).
  2. Inquiries about capacity utilization and sales initiatives at Warren Remedies.
  3. Questions about plans for additional CAPEX.
  4. Discussion on the contribution and future of Clarity Pharma business.
Indoco Remedies Ltd (INDOCO) Concall Report Analysis & Insights | Dhanarthi